Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia

Basit Öğe Kaydı
dc.authoridCakir, Halil Mete/0000-0001-7085-1618
dc.authoridELVERDI, TUGRUL/0000-0001-9496-5353
dc.contributor.authorSonmez, Oezge
dc.contributor.authorYurttas, Nurguel Ozguer
dc.contributor.authorIhtiyaroglu, Ilker
dc.contributor.authorCakir, Halil Mete
dc.contributor.authorAtli, Zeynep
dc.contributor.authorElverdi, Tugrul
dc.contributor.authorSalihoglu, Ayse
dc.date.accessioned2025-03-23T19:41:52Z
dc.date.available2025-03-23T19:41:52Z
dc.date.issued2024
dc.departmentSinop Üniversitesi
dc.description.abstractIn this study, we evaluated the possible kidney toxicity of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). We examined 195 patients with CML and 138 patients with chronic kidney disease (CKD). We found a downward trend in the glomerular filtration rate under TKI treatment during follow up which was comparable to that of CKD patients. Introduction: The advent of tyrosine kinase inhibitors (TKIs) was revolutionary in the management of chronic myeloid leukemia (CML). Although TKIs were generally considered to be safe, they can be associated with renal injury. We evaluated the effect of TKIs on renal functions in a cohort of patients with long-term follow-up. Material and Methods: We retrospectively examined patients with chronic phase CML treated with TKIs. We analyzed the estimated glomerular filtration rate (eGFR) of patients from the initiation of TKI to the last follow-up. eGFR values of CML patients were compared to those of patients with stage 1 or 2 chronic kidney disease (CKD). Results: A total of 195 patients with CML and 138 patients with CKD were examined. eGFR decline was 1.556 ml/min/1.73m 2 /year for patients with CML ( P = .221). Patients receiving second-generation TKIs (2GTKI) were estimated to have 0.583 ml/min/1.73m 2 higher eGFR value than that of the imatinib group, but it was not significant ( P = .871). eGFR of patients who had used bosutinib had a downward trend. Duration of TKI therapy, age, and hypertension were found to be significant factors in eGFR decline for CML patients. Lower baseline GFR was associated with an increased risk of CKD development. Conclusion: Imatinib could result in a decline in eGFR which was clinically similar to early-stage CKD patients. We did not observe significant kidney function deterioration in patients receiving 2GTKIs including dasatinib and nilotinib. We recommend close renal function monitoring in patients receiving imatinib, especially for elderly patients with lower baseline eGFR and hypertension.
dc.identifier.doi10.1016/j.clml.2023.12.004
dc.identifier.endpage239
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue4
dc.identifier.pmid38281820
dc.identifier.scopus2-s2.0-85184245718
dc.identifier.scopusqualityQ3
dc.identifier.startpage232
dc.identifier.urihttps://doi.org/10.1016/j.clml.2023.12.004
dc.identifier.urihttps://hdl.handle.net/11486/6667
dc.identifier.volume24
dc.identifier.wosWOS:001222888200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCig Media Group, Lp
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectChronic kidney disease
dc.subjectChronic myeloid leukemia
dc.subjectCML
dc.subjectGlomerular filtration rate
dc.subjectImatinib
dc.titleEffect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu